Cutaneous toxicities, commonly defined as rash, acne, pruritus and dry skin, have been reported as one of the predominant side effects in cancer patients treated with small-molecule tyrosine kinase inhibitors (TKI) of EGFR (gefitinib, erlotinib), dual EGFR/HER2 (lapatinib) inhibitors, pan-HER (CI-1033) inhibitors and anti-EGFR antibodies (cetuximab, ABX-EGF and EMD72000) (Busam et al, 2001; Hidalgo et al, 2001; Shin et al, 2001; Fukuoka et al, 2003; Kris et al, 2003; Burris, 2004; Rowinsky et al, 2004; Vanhoefer et al, 2004). This evidence concerns the gene ERBB2 and cancer.